and Objectives There is a paucity of published cost-eff ectiveness studies of alternative scenarios in depressive episode acute medical care in Eastern European populations. Methods Prospective cost-eff ectiveness analysis was conducted on 65 depressive patients in a large university clinic [May 2010-February 2012. Patient visits to attending psychiatrists were scheduled at baseline, 3rd and 8th week. HDRS-17 was deployed to assess clinical effi ciency and Q-LES-Q-SF scale for life quality

more »

... sment. Resource use and costs were evidenced from the Clinic's electronic registry of discharge invoices [national currency 1 €≈115.85 CSD]. Societal perspective and time horizon of 14 weeks were adopted. Results No statistically signifi cant diff erence in HDRS scores before and after introducing treatment [χ2=4.339; р=0.362]. QALY value increased by the following: 11.77 of the SSRI, 8.93 of the SNRI, and 12.54 of the heterocyclic antidepressant group. Mean ICERs were: SSRI to SNRI [-44,148 CSD/QALY]; SNRI to Heterocyclics [-45,716 CSD/QALY]; Heterocyclics to SSRI [-51,501 CSD/QALY]. Therapeutic response in increment free days: 28.69 days gained SSRI, 21.78 days SNRI, 30.59 days in heterocyclics. Incremental cost per additional depression free day gained was for: SSRI 346.38 CSD per day, SNRI 327.74 CSD, and heterocyclics 201.54 CSD. 235